Search results for "Biologicals"

showing 4 items of 4 documents

Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

2019

BACKGROUND: The lack of centralised data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardised data collection, subsequently enabling data interoperability.OBJECTIVES: To create a standardised list of variables for the first international registry for severe asthma via expert consensus.METHODS: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process…

MaleConsensusInternationalityDelphi TechniqueeducationDelphi method03 medical and health sciences0302 clinical medicineDisease registryWorkbookHumansImmunology and AllergyMedicineMedical historyRegistries030212 general & internal medicineCase report formcomputer.programming_languageData collectionbusiness.industryasthmamedicine.diseaseInverse synthetic aperture radar030228 respiratory systembiologicalsREGISTRYFemaleMedical emergencybusinesscomputerDelphiSpecialization
researchProduct

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct

The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor

2019

Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of rho kinase activity can reduce these activities, but may also lead to side effects, for instance systemic hypotension. This can be circumvented by liver-specific delivery of a rho kinase inhibitor to effector cells. Therefore, we targeted the rho kinase inhibitor Y27632 to the key pathogenic cells in liver fibrosis, i.e. myofibroblasts including activated HSCs that highly express the PDGF beta-receptor, using the drug carrier pPB-MSA. This carrier consists of mou…

Liver CirrhosisDrug targetingPyridinesPolymeric microspheresPharmaceutical Science02 engineering and technologyPharmacologychemistry.chemical_compoundY-27632FibrosisControlled releaseRho-associated protein kinaseMice Knockout0303 health sciencesDrug Carriersrho-Associated KinasesChemistryCIRRHOTIC RATS021001 nanoscience & nanotechnologyMicrospheresY-27632Drug deliveryFemale0210 nano-technologyDrug carrierATP Binding Cassette Transporter Subfamily BSIGNALING CONTRIBUTESLiver fibrosisBiologicalsHEPATIC STELLATE CELLSCell LineMECHANISMSReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesDELIVERYROCK INHIBITORmedicineAnimalsHumansProtein Kinase Inhibitors030304 developmental biologyProtein deliveryPORTAL PRESSUREmedicine.diseaseAmidesTargeted drug deliveryRho kinase inhibitorDelayed-Action PreparationsHepatic stellate cellVASODILATIONJournal of Controlled Release
researchProduct

Prioritizing care for severe asthma during SARS-CoV-2 pandemic

2021

Background Almost the entire World is experiencing the Coronavirus-Disease-2019 (COVID-19) pandemic, responsible, at the end of May 2020, of more than five million people infected worldwide and about 350,000 deaths. In this context, a deep reorganization of allergy clinics, in order to ensure proper diagnosis and care despite of social distancing measures expose, is needed. Main text The reorganization of allergy clinics should include programmed checks for severe and poorly controlled patients, application of digital medicine service for mild-to-moderate disease in well-controlled ones, postponement of non urgent diagnostic work-ups and domiciliation of therapies, whenever possible. As far…

Pulmonary and Respiratory MedicineDigital medicine service2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)AllergyPandemicbusiness.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaMEDLINECOVID-19ReviewBiologicalsasthmaSettore MED/10 - Malattie Dell'Apparato RespiratorioVirologyTelemedicineArticlePandemicHome deliveryMedicineImmunotherapybusiness
researchProduct